| Business Summary | | Geron
Corporation
is
a
biopharmaceutical
company
focused
on
discovering,
developing
and
commercializing
therapeutic
and
diagnostic
products
for
applications
in
oncology
and
regenerative
medicine,
and
research
tools
for
drug
discovery.
Geron's
product
development
programs
are
based
upon
three
patented
core
technologies:
telomerase,
human
embryonic
stem
cells
and
nuclear
transfer.
By
activating
telomerase,
the
Company
seeks
to
increase
the
lifespan
of
normal
cells,
which
have
prematurely
aged
in
the
body
to
treat
chronic
degenerative
diseases.
Conversely,
by
inhibiting
telomerase
the
Company
hopes
to
kill
cancer
cells
where
telomerase
is
abnormally
turned
on
and
to
diagnose
cancer
by
measuring
telomerase
activity.
Human
embryonic
stem
cells
can
develop
and
differentiate
into
all
cells
and
tissues
in
the
body.
Nuclear
transfer
is
a
method
for
generating
human
cells
or
whole
animals
from
genetic
material
derived
solely
from
the
nucleus
of
a
single
cell
obtained
from
a
single
individual. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Geron
Corporation
is
engaged
in
the
discovery
and
development
of
therapeutic
and
diagnostic
products
used
to
treat
cancer
and
age-related
degenerative
diseases.
For
the
six
months
ended
6/30/01,
revenues
decreased
22%
to
$2.4
million.
Net
loss
decreased
46%
to
$13.5
million.
Revenues
reflect
a
decrease
collaborative
agreements
due
the
regaining
of
rights
from
Pharmacia.
Lower
loss
reflects
lower
interest
expenses
related
to
convertible
debentures. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Alexander Barkas, Ph.D., 53 Chairman | -- | -- | Thomas Okarma, Ph.D., M.D., 55 Pres,
CEO, Director | $395K | -- | David Greenwood, 49 CFO,
Sr. VP - Corp. Devel., Sec., Treasurer | 280K | $1.1M | William Stempel, 47 VP,
Gen. Counsel | -- | -- | Jeannine Niacaris, 48 VP,
HR and Admin. Services | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|